CNS Pharmaceuticals (NASDAQ:CNSP – Get Free Report) and Tiziana Life Sciences (NASDAQ:TLSA – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, risk, profitability, institutional ownership, valuation and analyst recommendations.
Profitability
This table compares CNS Pharmaceuticals and Tiziana Life Sciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| CNS Pharmaceuticals | N/A | -238.68% | -166.30% |
| Tiziana Life Sciences | N/A | N/A | N/A |
Analyst Ratings
This is a breakdown of recent ratings and target prices for CNS Pharmaceuticals and Tiziana Life Sciences, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| CNS Pharmaceuticals | 1 | 0 | 1 | 0 | 2.00 |
| Tiziana Life Sciences | 1 | 1 | 0 | 0 | 1.50 |
Valuation & Earnings
This table compares CNS Pharmaceuticals and Tiziana Life Sciences”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| CNS Pharmaceuticals | N/A | N/A | -$15.85 million | ($29.63) | -0.18 |
| Tiziana Life Sciences | N/A | N/A | -$18.43 million | N/A | N/A |
Risk & Volatility
CNS Pharmaceuticals has a beta of 3.06, indicating that its share price is 206% more volatile than the S&P 500. Comparatively, Tiziana Life Sciences has a beta of 0.46, indicating that its share price is 54% less volatile than the S&P 500.
Institutional & Insider Ownership
14.0% of CNS Pharmaceuticals shares are owned by institutional investors. 0.0% of CNS Pharmaceuticals shares are owned by company insiders. Comparatively, 39.8% of Tiziana Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Summary
CNS Pharmaceuticals beats Tiziana Life Sciences on 6 of the 9 factors compared between the two stocks.
About CNS Pharmaceuticals
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc., Reata Pharmaceuticals, Inc., Pomeranian Medical University, and The University of Texas M.D. Anderson Cancer Center; and a development agreement with WPD Pharmaceuticals Inc. The company was incorporated in 2017 and is based in Houston, Texas.
About Tiziana Life Sciences
Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti- receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.Kingdom.
Receive News & Ratings for CNS Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CNS Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
